Cargando…

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes. We wanted to determine whether measuring BCR-ABL1 mRNA doubling-times (DTs) could disting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pennisi, Maria Stella, Stella, Stefania, Vitale, Silvia Rita, Puma, Adriana, Di Gregorio, Sandra, Romano, Chiara, Tirrò, Elena, Massimino, Michele, Antolino, Agostino, Siragusa, Sergio, Mannina, Donato, Impera, Stefana, Musolino, Caterina, Mineo, Giuseppe, Martino, Bruno, Zammit, Valentina, Di Raimondo, Francesco, Manzella, Livia, Stagno, Fabio, Vigneri, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700306/ https://www.ncbi.nlm.nih.gov/pubmed/31456947 http://dx.doi.org/10.3389/fonc.2019.00764

Ejemplares similares

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
por: Stella, Stefania, et al.
Publicado: (2019)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
por: Massimino, Michele, et al.
Publicado: (2021)

Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells
por: Massimino, Michele, et al.
Publicado: (2021)

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
por: Massimino, Michele, et al.
Publicado: (2018)

High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability
por: Massimino, Michele, et al.
Publicado: (2023)

A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic
por: Stella, Stefania, et al.
Publicado: (2021)

New Insights in Thyroid Cancer and p53 Family Proteins
por: Manzella, Livia, et al.
Publicado: (2017)

Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients
por: Stella, Stefania, et al.
Publicado: (2022)

The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy
por: Vigneri, Paolo Giovanni, et al.
Publicado: (2015)

Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes
por: Stella, Stefania, et al.
Publicado: (2021)

Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma
por: Tirrò, Elena, et al.
Publicado: (2021)

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
por: Tirrò, Elena, et al.
Publicado: (2019)

Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment
por: Manzella, Livia, et al.
Publicado: (2019)

Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
por: Tirrò, Elena, et al.
Publicado: (2019)

Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer
por: Romano, Chiara, et al.
Publicado: (2021)

Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports
por: Pennisi, Maria Stella, et al.
Publicado: (2023)

Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far
por: Stella, Stefania, et al.
Publicado: (2023)

Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels
por: Ceran, Funda, et al.
Publicado: (2022)

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques
por: Recchia, Anna Grazia, et al.
Publicado: (2015)

Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer
por: Massimino, Michele, et al.
Publicado: (2023)

Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells
por: Stella, Stefania, et al.
Publicado: (2023)

Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
por: Vaidya, Shantashri, et al.
Publicado: (2015)

Frequency of BCR-ABL Transcript Types in Syrian CML Patients
por: Farhat-Maghribi, Sulaf, et al.
Publicado: (2016)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities
por: Stella, Stefania, et al.
Publicado: (2021)

FISH mapping of Philadelphia negative BCR/ABL1 positive CML
por: Virgili, Anna, et al.
Publicado: (2008)

Loss of Gadd45b accelerates BCR-ABL-driven CML
por: Sha, Xiaojin, et al.
Publicado: (2018)

IMPENDING CARDIAC TAMPONADE AS THE INITIAL MANIFESTATION OF BCR-ABL-POSITIVE CML
por: Gaballa, Salem, et al.
Publicado: (2020)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
por: Clapper, Erin, et al.
Publicado: (2020)

Alternative splicing of flowering time gene FT is associated with halving of time to flowering in coconut
por: Xia, Wei, et al.
Publicado: (2020)

Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting
por: Agarwal, Mohan B.
Publicado: (2014)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias
por: Stella, Stefania, et al.
Publicado: (2019)

Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence
por: Burchert, Andreas
Publicado: (2014)

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report
por: Ostendorf, Benjamin N, et al.
Publicado: (2015)

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
por: Kockerols, Camille C.B., et al.
Publicado: (2020)

Genome Halving with an Outgroup
por: Zheng, Chunfang, et al.
Publicado: (2007)

Osteoarthritis and the Rule of Halves
por: Sheikh, L., et al.
Publicado: (2014)

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
por: Watanabe, Kousuke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6mh1nnc1m88dc5cqolhj8ijeh6